142 related articles for article (PubMed ID: 38254917)
1. The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.
Aguilar-Mahecha A; Alirezaie N; Lafleur J; Bareke E; Przybytkowski E; Lan C; Cavallone L; Salem M; Pelmus M; Aleynikova O; Greenwood C; Lovato A; Ferrario C; Boileau JF; Mihalcioiu C; Roy JA; Marcus E; Discepola F; Majewski J; Basik M
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254917
[TBL] [Abstract][Full Text] [Related]
2. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome.
Powles RL; Wali VB; Li X; Barlow WE; Nahleh Z; Thompson AM; Godwin AK; Hatzis C; Pusztai L
Clin Cancer Res; 2020 Apr; 26(8):1977-1984. PubMed ID: 31919134
[TBL] [Abstract][Full Text] [Related]
4. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
5. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
6. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.
Lips EH; Michaut M; Hoogstraat M; Mulder L; Besselink NJ; Koudijs MJ; Cuppen E; Voest EE; Bernards R; Nederlof PM; Wesseling J; Rodenhuis S; Wessels LF;
Breast Cancer Res; 2015 Oct; 17(1):134. PubMed ID: 26433948
[TBL] [Abstract][Full Text] [Related]
8. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
9. Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.
Tang X; Thompson KJ; Kalari KR; Sinnwell JP; Suman VJ; Vedell PT; McLaughlin SA; Northfelt DW; Aspitia AM; Gray RJ; Carter JM; Weinshilboum R; Wang L; Boughey JC; Goetz MP
Breast Cancer Res; 2023 May; 25(1):57. PubMed ID: 37226243
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Jiang T; Shi W; Wali VB; Pongor LS; Li C; Lau R; Győrffy B; Lifton RP; Symmans WF; Pusztai L; Hatzis C
PLoS Med; 2016 Dec; 13(12):e1002193. PubMed ID: 27959926
[TBL] [Abstract][Full Text] [Related]
11. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Ademuyiwa FO; Chen I; Luo J; Rimawi MF; Hagemann IS; Fisk B; Jeffers G; Skidmore ZL; Basu A; Richters M; Ma CX; Weilbaecher K; Davis J; Suresh R; Peterson LL; Bose R; Bagegni N; Rigden CE; Frith A; Rearden TP; Hernandez-Aya LF; Roshal A; Clifton K; Opyrchal M; Akintola-Ogunremi O; Lee BH; Ferrando-Martinez S; Church SE; Anurag M; Ellis MJ; Gao F; Gillanders W; Griffith OL; Griffith M
Breast Cancer Res Treat; 2021 Aug; 189(1):187-202. PubMed ID: 34173924
[TBL] [Abstract][Full Text] [Related]
12. Incidence of BRCA1 somatic mutations and response to neoadjuvant chemotherapy in Chinese women with triple-negative breast cancer.
Li M; Zhang J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Gene; 2016 Jun; 584(1):26-30. PubMed ID: 26956035
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease.
Singh A; Georgy JT; Dhananjayan S; Sigamani E; John AO; Joel A; Chandramohan J; Abarna R; Rebekah G; Backianathan S; Abraham DT; Paul MJ; Chacko RT; Manipadam MT; Pai R
Gene; 2024 Feb; 895():147980. PubMed ID: 37951371
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Telli ML; Jensen KC; Vinayak S; Kurian AW; Lipson JA; Flaherty PJ; Timms K; Abkevich V; Schackmann EA; Wapnir IL; Carlson RW; Chang PJ; Sparano JA; Head B; Goldstein LJ; Haley B; Dakhil SR; Reid JE; Hartman AR; Manola J; Ford JM
J Clin Oncol; 2015 Jun; 33(17):1895-901. PubMed ID: 25847929
[TBL] [Abstract][Full Text] [Related]
15. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
16. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
[TBL] [Abstract][Full Text] [Related]
17. CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer.
Zhao ZM; Yost SE; Hutchinson KE; Li SM; Yuan YC; Noorbakhsh J; Liu Z; Warden C; Johnson RM; Wu X; Chuang JH; Yuan Y
BMC Cancer; 2019 Jan; 19(1):96. PubMed ID: 30665374
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM; Giltnane JM; Wang K; Schwarz LJ; Young CD; Cook RS; Owens P; Sanders ME; Kuba MG; Sánchez V; Kurupi R; Moore PD; Pinto JA; Doimi FD; Gómez H; Horiuchi D; Goga A; Lehmann BD; Bauer JA; Pietenpol JA; Ross JS; Palmer GA; Yelensky R; Cronin M; Miller VA; Stephens PJ; Arteaga CL
Cancer Discov; 2014 Feb; 4(2):232-45. PubMed ID: 24356096
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
[TBL] [Abstract][Full Text] [Related]
20. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J; Yao L; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2021 Feb; 148(4):941-949. PubMed ID: 32720318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]